Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Non-Hodgkin Lymphoma
Retrovirally Naïve HIV+ Patients With Non-Hodgkin Lymphoma Can Be Treated With Standard Chemotherapy
Researchers investigated the efficacy and safety of CHOP-like therapy for treatment-naïve patients with simultaneous diagnoses of NHL and HIV-positive.
Improving the Clinical Diagnosis and Classification of Gray Zone Lymphomas
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Diagnostic Delay in Diffuse Large B-Cell Lymphoma Linked to Poorer Outcomes for Patients With Worse Disease
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
FDA Greenlights New Rituxan Biosimilar
This US FDA has approved Ruxience for the treatment of adult patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Risk of Developing Certain Second Cancers May Vary According to non-Hodgkin Lymphoma Subtype
A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
